Analyst consensus rating
Arcutis Biotherapeutics Analyst Rating: Strong Buy
ARQT is rated Strong Buy by 8 analysts with a $36.88 target. As of 2026-08-27.
Direct answer
Arcutis Biotherapeutics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $36.88.
Forecast evidence checked August 27, 2026.
Get free Arcutis Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $25.14
- Average price target
- $36.88
- High price target
- $40.00
- Low price target
- $34.00
- Low target gap
- +35.2%
- Target upside
- +46.7%
- High target gap
- +59.1%
- Target range width
- 23.9%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arcutis Biotherapeutics?
Arcutis Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $36.88.
How far are Arcutis Biotherapeutics's low and high targets from the recorded price?
The low target implies +35.2%, while the high target implies +59.1%.
How many analysts are included in Arcutis Biotherapeutics's consensus?
The verified consensus includes 8 analysts.
How is Arcutis Biotherapeutics's target upside or downside calculated?
The average target of $36.88 is divided by the recorded price of $25.14, then one is subtracted to produce +46.7%. This does not guarantee a future return.
When was Arcutis Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.